What Each Compound Is
In the published literature, CJC-1295 is described as a long-acting analog of growth-hormone-releasing factor (GRF/GHRH), built on the hGRF(1-29) fragment and engineered with a chemistry that covalently links the peptide to circulating plasma proteins such as albumin. Researchers have characterized this bioconjugation as the basis for its extended presence in plasma in animal models (Teichman-related work; PMID 15817669). Ipamorelin, by contrast, is described as a synthetic pentapeptide and a selective growth-hormone secretagogue that acts as an agonist of the ghrelin receptor (GHS-R), first reported by Raun and colleagues (PMID 9849822). The two are therefore studied as distinct molecular classes: a GHRH-receptor analog versus a ghrelin-receptor agonist. Both have been examined in the context of the somatotropic axis in non-human systems.
How Their Studied Mechanisms Differ
The literature frames the two peptides as engaging the GH axis through separate, complementary receptors. CJC-1295 has been studied as acting on the GRF (GHRH) receptor of the anterior pituitary; in rat models, hGRF(1-29)-albumin bioconjugates were reported to activate that receptor and produce a roughly four-fold increase in GH area-under-the-curve over a two-hour window compared with unmodified hGRF(1-29), with the compound detectable in plasma beyond 72 hours (PMID 15817669). Ipamorelin has been characterized as binding the ghrelin/GHS receptor to elicit GH release. A frequently cited point in the preclinical record is its reported selectivity: in the original characterization, researchers observed GH release without significantly raising ACTH or cortisol relative to GHRH, even at doses well above the ED50 for GH release in animals (PMID 9849822). Researchers have separately asked whether GH-releasing peptides like this act as ghrelin secretagogues (PMID 11322495).
Research Areas and Models Where Each Appears
CJC-1295 appears in the literature largely around pharmacokinetics, the GH/IGF-1 axis, and analytical detection. Work on the GH/IGF-1 axis reported serum protein-profile changes in adult subjects after administration of the long-acting GHRH analog (PMID 19386527), and a substantial body of method-development literature addresses detecting CJC-1295 and related GHRH analogs in biological matrices, reflecting its status on anti-doping prohibited lists. Ipamorelin, beyond its founding GH-secretagogue characterization, also recurs in models unrelated to GH output: it has been studied as a ghrelin mimetic in a rodent model of postoperative ileus, where investigators examined gastrointestinal motility (PMID 19289567). This gastrointestinal/motility line of inquiry is largely specific to the ghrelin-receptor class and does not feature in the CJC-1295 record.
Which the Literature Studies for What
Read neutrally, the two peptides occupy different niches in the research record. CJC-1295 is predominantly studied as a tool for understanding long-acting GHRH-receptor activation, sustained GH/IGF-1 axis stimulation, and the analytical chemistry of detecting such analogs (PMIDs 15817669, 19386527). Ipamorelin is predominantly studied as a model selective ghrelin-receptor agonist - useful where investigators want GH-axis engagement reported as relatively specific to GH, and separately as a probe in gastrointestinal-motility models (PMIDs 9849822, 19289567, 11322495). Some experimental designs in the broader literature have examined GHRH-type and GHS-type agents together because their mechanisms are described as acting at different receptors on the same axis. None of this should be read as guidance for use; it is a summary of how published studies have framed each compound in non-human and in-vitro settings.
Summary Comparison
In short, the literature treats CJC-1295 as a long-acting GHRH-receptor analog defined by its albumin-conjugation chemistry and extended plasma presence, studied mainly around GH/IGF-1 pharmacokinetics and analytical detection. It treats Ipamorelin as a selective ghrelin-receptor agonist defined by reported GH-release selectivity, studied around GH secretagogue characterization and gastrointestinal-motility models. The compounds differ in peptide class, receptor target, the duration profile reported in animals, and the experimental questions researchers attach to them. Any comparison here describes the published research record only and is not an endorsement, recommendation, or instruction to administer either compound.
How VANTA Verifies Both
VANTA supplies CJC-1295 and Ipamorelin strictly as reference-grade materials for laboratory research use only - not for human or animal consumption, and not for any therapeutic application. Each compound is characterized for identity and purity by HPLC (high-performance liquid chromatography) and confirmed by mass spectrometry, and every lot ships with a per-batch Certificate of Analysis (COA) documenting those results. This verification supports analytical reproducibility for researchers; it is not a safety or efficacy claim of any kind.
References
- 1.Jetté et al. (2005) - Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology.
- 2.Raun et al. (1998) - Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol.
- 3.Sackmann-Sala et al. (2009) - Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res.
- 4.Venkova et al. (2009) - Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther.
- 5.Ahnfelt-Rønne et al. (2001) - Do growth hormone-releasing peptides act as ghrelin secretagogues? Endocrine.